<DOC>
	<DOCNO>NCT01073696</DOCNO>
	<brief_summary>The purpose study determine effect heat apply granisetron transdermal patch healthy subject .</brief_summary>
	<brief_title>Effect External Heat Transdermal Granisetron Patch Pharmacokinetics ( PK ) Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Granisetron</mesh_term>
	<criteria>Healthy male female subject age ≥ 18 ≤ 45 year screen . Subjects must demonstrate understanding purpose risk study agree follow restriction schedule study procedure , evidence voluntary write informed consent ( sign date ) obtain take part trialrelated activity . Any current previous disease , disorder , allergy condition ( include recent unexplained weight loss ) could affect study conduct laboratory assessment , present undue risk study medication procedure . Hypersensitivity adhesive plaster surgical tape . Any physical examination screen investigation result indicate subject unfit study . Scarring upper arm , include extensive tattoo make skin reaction unevaluable . A positive virology test , urine test drug abuse , pregnancy test result ( female childbearing potential ) . Recent use prescribe overthecounter medication , opinion Investigator Sponsor , interfere study procedure compromise safety . Received investigational drug within 3 month ( 90 day ) precede patch application . Loss ≥ 400 mL blood ( e.g . blood donor ) within past 3 month . Average weekly alcohol consumption great 21 unit ( male ) 14 unit ( female ) , habitually smoke ≥ 5 cigarette equivalent tobacco per day within 6 month patch application . Subjects may smoke confine study site . Subjects must consume alcohol , xanthinecontaining food drink within 48 hour prior dose discharge . Lactating female subject , female subject childbearing potential willing use acceptable form contraception screen visit , study 90 day study . Employee Investigator study centre , direct involvement propose study study direction Investigator study centre , well family member employee Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Sancuso</keyword>
	<keyword>granisetron</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>